| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-14-0957 |
| P698 | PubMed publication ID | 24986517 |
| P50 | author | Mark J. Smyth | Q38544864 |
| P2093 | author name string | John Stagg | |
| Michele W L Teng | |||
| Deepak Mittal | |||
| Bertrand Allard | |||
| Arabella Young | |||
| Michelle Yong | |||
| Kimberley Stannard | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3652-3658 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor | |
| P478 | volume | 74 |
| Q26749571 | A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment |
| Q33763266 | A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment |
| Q64088623 | A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy |
| Q92436831 | A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model |
| Q38900954 | A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer |
| Q93335849 | A2A adenosine receptor functional states characterized by 19F-NMR |
| Q28087576 | A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy |
| Q92628370 | Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis |
| Q39148961 | Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. |
| Q90704170 | Adenosinergic signaling as a target for natural killer cell immunotherapy |
| Q38714704 | Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia |
| Q64253586 | Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? |
| Q33771631 | Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma |
| Q64093247 | CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy |
| Q90606613 | CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q37012714 | CD73-adenosine reduces immune responses and survival in ovarian cancer patients |
| Q38711094 | CD73-adenosine: a next-generation target in immuno-oncology |
| Q36107945 | CD73: A potential biomarker for anti-PD-1 therapy |
| Q49788493 | Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells |
| Q47395423 | Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. |
| Q34936598 | Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis |
| Q28066199 | Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy |
| Q38645178 | Combination cancer immunotherapies tailored to the tumour microenvironment |
| Q64997781 | Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. |
| Q38809772 | Emerging Opportunities and Challenges in Cancer Immunotherapy. |
| Q38870205 | Extracellular purines, purinergic receptors and tumor growth. |
| Q58568628 | GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures |
| Q90441910 | Harnessing innate immunity in cancer therapy |
| Q36024656 | Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). |
| Q92513092 | Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors |
| Q58802811 | Immunometabolism in cancer at a glance |
| Q91950939 | Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future |
| Q64953266 | Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. |
| Q89482545 | Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells |
| Q38747872 | Marked for death: targeting epigenetic changes in cancer |
| Q53037025 | Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. |
| Q41194053 | Mice lacking the chromodomain helicase DNA-binding 5 chromatin remodeler display autism-like characteristics |
| Q46026307 | Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. |
| Q90265781 | NK Cell Dysfunction and Checkpoint Immunotherapy |
| Q38601420 | Natural and therapy-induced immunosurveillance in breast cancer |
| Q92637629 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy |
| Q46047154 | New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone |
| Q52615722 | Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. |
| Q89574416 | Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients |
| Q37616736 | Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice. |
| Q38765118 | Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging |
| Q57192144 | Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy |
| Q37702792 | Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer |
| Q39198154 | Prospects for combining targeted and conventional cancer therapy with immunotherapy |
| Q50035774 | Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors |
| Q38753350 | Purinergic regulation of the immune system |
| Q39255886 | Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy |
| Q98735502 | Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies |
| Q53543423 | Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. |
| Q38998454 | Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. |
| Q38809776 | Reversing T-cell Dysfunction and Exhaustion in Cancer |
| Q39114281 | STATs in NK-Cells: The Good, the Bad, and the Ugly |
| Q90655148 | Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers |
| Q47131425 | Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab |
| Q39193878 | Successful and Maladaptive T Cell Aging |
| Q39125149 | Targeting A2 adenosine receptors in cancer |
| Q60921609 | Targeting Adenosine Receptor Signaling in Cancer Immunotherapy |
| Q93062525 | Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function |
| Q38956294 | Targeting PD-1/PD-L1 in lung cancer: current perspectives |
| Q55330380 | Targeting adenosine for cancer immunotherapy. |
| Q39235260 | Targeting adenosine in cancer immunotherapy: a review of recent progress. |
| Q46140918 | Targeting immunosuppressive adenosine in cancer |
| Q38829849 | Targeting natural killer cells in cancer immunotherapy |
| Q91598122 | Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy |
| Q48191363 | The Hypoxia-Adenosine Link during Intestinal Inflammation. |
| Q96230894 | The adenosine pathway in immuno-oncology |
| Q39161005 | The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets |
| Q90402575 | The evolving immunotherapeutic landscape in advanced oesophagogastric cancer |
| Q38666253 | The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. |
| Q49787788 | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
| Q107670795 | The regulation of immune checkpoints by the hypoxic tumor microenvironment |
| Q62745785 | The role of NK cells and CD39 in the immunological control of tumor metastases |
| Q37079141 | Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy |
| Q92282117 | Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response |
| Q90644277 | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer |
| Q87944215 | [B cells in head and neck oncology] |
Search more.